Excretion Pathways Based on the peptide structure and pharmacokinetic characteristics: Primary elimination likely occurs through hepatic metabolism and biliary excretion Renal excretion of intact peptide appears minimal given the molecular size and protein binding Clearance rates remain consistent across multiple doses, indicating no accumulation beyond steady-state Terminal elimination phase extends several days after the last dose The favorable pharmacokinetic profile, characterized by predictable absorption, limited drug interactions, and steady-state maintenance with weekly dosing, supports the clinical development strategy and dose escalation regimens employed in phase 2 and phase 3 trials
Hypoglycemia, which can impair cognition, is uncommon with GLP-1 monotherapy but risk increases when combined with insulin or sulfonylureas
Proven, FDA-approved medications help control the physical and psychological cravings that have undermined your previous efforts
The clinical data is clear: it does not
Due to the complex pathophysiology and heterogeneity of the disease phenotype, many patients with NAFLD may require combination therapy
